leisure time -WSS

leisure time

author：leisure time 2025-09-30 00:45:43 - browse：83297

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Amylyx ALS drug fails large clinical trial

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

WuXi Biologics beefs up its lobbying operation

HHS suspends federal funding for EcoHealth Alliance

Abbott's new stent may help patients with peripheral artery disease

With psoriasis trial ahead, Alumis raises $259 million

HHS suspends federal funding for EcoHealth Alliance

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Oak Street deal isn't the answer to health care's woes

Psychedelics group wrestles with new pharma identity

Change Healthcare cyberattack prompts Medicare loan program

Wildfire smoke exposes gaps in outdoor worker protections

Former medical device CEO who sold dummy, plastic parts convicted of fraud

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Tori Bowie and the unacceptable rates of Black maternal death

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

entertainment

RSV shot was 90% effective at preventing hospitalizations in kids

Sen. Paul opposes bill to ban Chinese biotechs

CDC marks new Covid

Free medical tuition alone isn't enough to close gaps in primary care

Sen. Paul opposes bill to ban Chinese biotechs

What it’s like to watch children die of measles

focus

hotspot

knowledge

leisure time